Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GE 226

Drug Profile

GE 226

Alternative Names: [18F]FBA-ZHER2:2891; [18F]GE-226; Fluorine-18 GE 226; GE-226

Latest Information Update: 28 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affibody; GE Healthcare
  • Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported HER2 positive breast cancer

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Diagnosis) in United Kingdom (IV, Injection)
  • 11 Jul 2022 18F GE 226 is available for licensing as of 11 Jul 2022. affibody.se/partnering/
  • 03 Jun 2022 Adverse events and pharmacokinetics data from a phase I trial in Breast caner presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top